Moderna Inc. ($MRNA) Stock Forecast: Up 7.6% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company renowned for its development of mRNA-based vaccines, such as the COVID-19 vaccine.

Why is Moderna Inc. going up?

MRNA stock is up 7.6% on Mar 6, 2025 16:05

• Company insiders purchasing shares valued at $6 million may indicate confidence in the company's future, leading to increased investor optimism and driving the stock price up.
• Unusual options activity, with a majority of investors entering trades with bullish expectations, added to positive sentiment around Moderna, contributing to the stock's strong upward movement.
• The blend of insider buying and bullish options activity likely triggered a domino effect, attracting more investors to participate in the upward trend and propelling MRNA stock to surge by 16% in a single day.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Here's Why Moderna Stock Soared 16% on Wednesday

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

https://www.zacks.com/stock/news/2426574/heres-why-moderna-stock-soared-16-on-wednesday

Moderna Unusual Options Activity - Moderna ( NASDAQ:MRNA )

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 14 trades. If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 35% ...

https://www.benzinga.com/insights/options/25/02/44053789/moderna-unusual-options-activity

Trending Today

Stellar ($XLM) Crypto Forecast: Down 5.2% Today

Litecoin ($LTC) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.2% Today

Cardano ($ADA) Crypto Forecast: Down 13.0% Today

Polkadot ($DOT) Crypto Forecast: Down 5.3% Today

Arkham ($ARKM) Crypto Forecast: Down 5.5% Today

Stox ($STX) Crypto Forecast: Down 5.2% Today

Solana ($SOL) Crypto Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Moderna Inc. Price History

26.01.2025 - MRNA Stock was down 5.5%

• Despite the prevailing positivity in the vaccine sector, MRNA displayed a bearish trend, possibly linked to profit-taking or concerns about the company's vaccine initiatives.
• The upward movement of other vaccine stocks implies investor confidence in the market prospects tied to the recent coronavirus discovery.
• MRNA's decline could be influenced by internal or market-specific factors rather than industry-wide trends.

04.01.2025 - MRNA Stock was down 6.8%

• Moderna's stock experienced a bearish trend today following an analyst's decision to downgrade the stock from Buy to Neutral and lower the price target. This downgrade, alongside reduced revenue expectations, likely impacted investor confidence negatively.
• While some investors showed bullish sentiment through options trading, overall market sentiment appears to have been influenced by the pessimistic outlook presented by the analyst.
• Noteworthy options trading activity, encompassing both bullish and bearish trades, suggests uncertainty and volatility surrounding Moderna's stock, potentially contributing to its decline.
• Investor wariness regarding Moderna's future earnings, particularly in anticipation of the forthcoming quarterly results, is evident. This caution aligns with discussions on biotech stocks poised to surpass Q4 earnings estimates.

20.01.2025 - MRNA Stock was down 5.2%

• Moderna (MRNA) revealed Q4 earnings that fell short of EPS predictions and displayed a decrease in revenue, prompting a downward trend in the market.
• The FDA's decision to pause Moderna's norovirus vaccine trial following a Guillain-Barré syndrome case possibly raised apprehensions among investors, impacting the stock negatively.
• Analysts expressing reservations and issuing downgrades on MRNA stock subsequent to the earnings report might have added to the bearish outlook.
• Despite surpassing revenue projections and confirming guidance, the drop in COVID vaccine sales could have also influenced the stock's decline.

03.01.2025 - MRNA Stock was down 5.1%

• Despite the general optimism towards Moderna, a recent downgrade from a prominent analyst at Goldman Sachs from Buy to Neutral, accompanied by a lower price target, led to a downward trend in the stock.
• The bullish outlook from investors in options trading did not seem to outweigh the impact of the analyst's downgrade.
• The contrast between the positive options activity and the analyst's downgrade potentially created uncertainty among investors, contributing to the decline in Moderna's stock price.

14.01.2025 - MRNA Stock was up 6.6%

• The company reported a Q4 loss but exceeded revenue estimates, indicating strong financial performance.
• Struggles with scaling down manufacturing and launching new products may have impacted its profitability.
• Investors may be optimistic about the company's future prospects, especially with the potential of its bird flu vaccine candidates and ongoing COVID-19 vaccine sales.
• The bullish movement in the company's stock could be a result of investors focusing on the positive revenue surprise and the long-term growth potential of its vaccine portfolio.

14.01.2025 - MRNA Stock was up 7.1%

• Moderna reported a mixed earnings result, surpassing revenue expectations while recording a larger loss than expected, which potentially caused initial uncertainty in the market.
• The bullish movement in Moderna's stock is possibly due to the market's focus on the company's initiatives to optimize manufacturing processes and introduce new products, showcasing resilience and adaptability within a challenging environment.
• Despite some investors taking a bearish stance in the options market initially, the overall positive sentiment regarding Moderna's future prospects and product pipeline likely eclipsed these short-term bearish signals.
• Investors seem hopeful about Moderna's long-term outlook, particularly with ongoing advancements in vaccine technology, and the company's demonstrated ability to navigate through changing market conditions, contributing to the positive stock movement.

11.01.2025 - MRNA Stock was down 5.3%

• Moderna (MRNA) experienced a bearish movement possibly due to profit-taking after recent surges in its stock price.
• Despite expectations of beating earnings estimates, investors may have been cautious about the company's pipeline updates.
• The focus on other biotech stocks reporting earnings this week may have shifted attention away from Moderna, leading to the bearish movement.
• The overall market sentiment towards biotech stocks and the anticipation of earnings reports could have influenced Moderna's stock performance negatively today.

27.01.2025 - MRNA Stock was down 5.5%

• The potential reconsideration of a substantial contract for a bird flu vaccine by a previous administration may have triggered concerns among investors, impacting Moderna's stock negatively.
• Despite this, the bullish outlook from investors with significant funds shows sustained belief in Moderna's future potential, implying the current decline might be temporary.
• The increased interest in vaccine stocks, including Moderna, following reports of a new coronavirus in China underscores the market's sensitivity to disease outbreaks, affecting companies specializing in vaccine research.

06.02.2025 - MRNA Stock was up 7.6%

• Company insiders purchasing shares valued at $6 million may indicate confidence in the company's future, leading to increased investor optimism and driving the stock price up.
• Unusual options activity, with a majority of investors entering trades with bullish expectations, added to positive sentiment around Moderna, contributing to the stock's strong upward movement.
• The blend of insider buying and bullish options activity likely triggered a domino effect, attracting more investors to participate in the upward trend and propelling MRNA stock to surge by 16% in a single day.

18.01.2025 - MRNA Stock was up 6.6%

• Moderna's (MRNA) stock displayed a significant uptrend during the last trading session.
• Despite reservations voiced by analysts and a decrease in ratings, the company's Q4 financial performance surpassed expectations, including higher revenues, and restated its total revenue projections for 2025.
• The reduction in COVID vaccine sales was counterbalanced by the revenue outperformance. However, a loss was reported due to the downsizing of manufacturing operations, instigating uncertainty in the market.
• Emphasis seems to be placed on the favorable earnings and revenue outcomes rather than the drop in the COVID business, fueling the upward momentum in the stock price.

18.01.2025 - MRNA Stock was up 6.2%

• Moderna reported Q4 earnings and revenues that beat expectations, despite a decline in COVID vaccine sales. This positive financial performance likely contributed to the bullish movement in the stock.
• Despite scaling down manufacturing and facing growing pains, Moderna's ability to surpass revenue estimates showcased its resilience and potential for future growth.
• The downgrade by a top Wall Street analyst for another company, Hims & Hers Health, may have shifted investor focus towards Moderna, leading to increased buying activity and driving the stock price higher.
• Overall, Moderna's strong financial results and ongoing efforts to launch new products seem to have overshadowed any concerns about its COVID business decline, fueling investor optimism and driving the bullish movement in the stock.

28.01.2025 - MRNA Stock was down 6.0%

• Unusual bullish options activity was detected for Moderna, indicating positive sentiment among investors.
• The reconsideration of a $590 million funding contract for a bird flu vaccine by officials may have raised uncertainty and impacted the stock negatively.
• Despite the bullish options trends, the news of potential funding withdrawal and a new coronavirus discovery in China affecting vaccine stocks likely contributed to Moderna's bearish movement.
• The overall market sentiment towards vaccine stocks seems to be mixed, with both positive and negative factors influencing Moderna's performance today.